India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#419- Valuation
- ₹11,950 Cr
2023 #374 2022 #409
Revenue · FY 2025
₹1,080.06 Cr
▲ 2% YoY
Net profit · FY 2025
₹233.5 Cr
Net margin 21.6%
EBITDA · FY 2025
₹208.01 Cr
EBITDA margin 19.3%
Authorised capital
₹1.12 Cr
Registered with MCA
Paid-up capital
₹53.99 Lakh
Issued & subscribed
Satisfied charges
₹9 Cr
No open charges
Company age
24 yrs
Est. 2002
Employees · EPFO
1,437
Provident fund records
About BDR Pharmaceuticals International Private Limited
Data last updated:
BDR Pharmaceuticals International Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 September 2002 and has been in existence for over 24 years.
Its director Dharmesh Shah and family are #399 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH2002PTC137329. Its GSTIN is 27AABCB9286B1ZO (Maharashtra). The company holds 15 GST registrations, of which 11 are active.
The company has an authorised share capital of ₹1.12 Cr and a paid-up capital of ₹53.99 Lakh. It is led by directors including Aravind Manappa Badiger and Jayesh Shantilal Trivedi.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 407 – 408 Sharda Chambers New Marine Lines, Mumbai, Maharashtra, India – 400020.
As per the financials filed for FY 2025, the company reported a revenue of ₹1,080.06 Cr, a growth of 2% compared to the previous year. For the same year it recorded a net profit of ₹233.5 Cr (net margin 21.6%) and EBITDA of ₹208.01 Cr (EBITDA margin 19.3%). Revenue has grown at a compounded annual rate (CAGR) of 12% over three years and 14% over five years.
The company has about 1,437 employees on its provident fund (EPFO) records. Its group structure includes 6 subsidiaries.
The company is associated with 1 brand: BDR Pharmaceuticals Internationals. As per MCA filings, the company has satisfied charges of ₹9 Cr on record. Court records list 55 cases involving the company, including 38 filed by the company and 17 filed against it; 27 cases are pending. The company has 6 deals on record (3 funding rounds, 3 secondary share transfers), with disclosed funding of ₹750.47 Cr; the latest was in September 2024. Its 10 peer companies in the Pharma industry (API Manufacturers, Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Cipla Health Limited with revenue of ₹1,228.87 Cr. The company has 16 MSME Form 1 returns on record between 2019 and 2024, listing 667 overdue payments to 32 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bdrpharma.com.
Company details
CIN U24230MH2002PTC137329
Registration Number 137329
Incorporation Date 24 September 2002
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Aravind Manappa Badiger Director Jayesh Shantilal Trivedi Director Tejash Vijay Shah Director Recognitions & Rankings of BDR Pharmaceuticals International
India's Richest People 2026 edition · 1 director · Source: Hurun India
- #399 Dharmesh Shah & family ₹9,300 Cr
Contact details
BDR Pharmaceuticals International Private Limited's registered office is in Mumbai, Maharashtra. Its website is bdrpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address407 – 408 Sharda Chambers New Marine Lines, Mumbai, Maharashtra, India – 400020
- IndustryPharma, Drug Formulation & Development, API Manufacturers
To see the full contact details of BDR Pharmaceuticals International Private Limited, buy the company report.
Comprehensive company report
BDR Pharmaceuticals International Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
BDR Pharmaceuticals International operates one associated brand: BDR Pharmaceuticals Internationals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| APIs and finished products are developed and manufactured. | bdrpharma.com |
Business activity
The main business activity of BDR Pharmaceuticals International is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of BDR Pharmaceuticals International Private Limited, buy the company report.
Financials of BDR Pharmaceuticals International Private Limited
FY 2025 filings availableBDR Pharmaceuticals International Private Limited reported revenue of ₹1,080.06 Cr (up 2% YoY) for FY 2025.
Revenue · FY 2025
₹1,080.06 Cr ▲ 2%
Net profit · FY 2025
₹233.5 Cr margin 21.6%
EBITDA · FY 2025
₹208.01 Cr margin 19.3%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 2%
3 years · compounded
▼ 12%
5 years · compounded
▲ 14%
EBITDA CAGR growth
1 year
▼ 12%
3 years · compounded
▼ 28%
5 years · compounded
▲ 6%
Revenue has grown at a compounded annual rate (CAGR) of 14% over five years, including 2% growth in the latest year. EBITDA fell 12% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹1,080.06 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹208.01 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹233.5 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 19.3% | ||||
| Net Profit Margin | 21.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of BDR Pharmaceuticals International Private Limited, buy the company report.
Board of directors of BDR Pharmaceuticals International Private Limited
BDR Pharmaceuticals International has 6 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Aravind Manappa Badiger | Director | 15 Dec 2012 | 13 Years 10 Months | Current |
| Jayesh Shantilal Trivedi | Director | 04 Dec 2020 | 5 Years 10 Months | Current |
| Tejash Vijay Shah Also directs: Majorelle LLP, BDR Lifesciences Private Limited, Magnum Chemi-Gran Private Limited and 1 more | Director | 16 Jan 2008 | 18 Years 9 Months | Current |
| Dharmesh Mahendra Shah | Director | 13 May 2022 | 4 Years 5 Months | Current |
| Manish Gaur Also directs: Zenex Animal Health India Private Limited, Qburst Technologies Private Limited, Qburst Software Services Private Limited and 1 more | Nominee Director | 12 May 2022 | 4 Years 5 Months | Current |
| Raheel Dharmesh Shah Also directs: BDR Lifesciences Private Limited, Magnum Chemi-Gran Private Limited, Nutrigene Biosciences Private Limited and 3 more | Director | 27 Jul 2011 | 15 Years 3 Months | Current |
Peer comparison
BDR Pharmaceuticals International Private Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Cipla Health Limited | ₹1,228.87 Cr (FY 2025) | 17.0% | Mumbai, Maharashtra, India | |||
| Neon Laboratories Limited | ₹1,222.81 Cr (FY 2025) | 4.0% | Mumbai, Maharashtra, India | |||
| Corona Remedies Limited | ₹1,202.35 Cr (FY 2025) | 18.0% | Ahmedabad, Gujarat, India | |||
| Hetero Healthcare Limited | ₹1,189.8 Cr (FY 2025) | 16.0% | Hyderabad, Telangana, India | |||
| Vasudha Pharma Chem Limited | ₹1,174.19 Cr (FY 2025) | 1.0% | Hyderabad, Telangana, India | |||
| Tirupati Medicare Limited | ₹1,119.15 Cr (FY 2025) | 6.0% | New Delhi, Delhi, India | |||
| Zuventus Healthcare Limited | ₹1,117.95 Cr (FY 2025) | 4.0% | Pune, Maharashtra, India | |||
| Medley Pharmaceuticals Limited | ₹1,114.92 Cr (FY 2025) | 8.0% | Mumbai, Maharashtra, India | |||
| Metrochem Api Private Limited | ₹1,107 Cr (FY 2025) | 1.0% | Hyderabad, Telangana, India | |||
| Troikaa Pharmaceuticals Limited | ₹1,088.44 Cr (FY 2025) | 12.0% | Ahmedabad, Gujarat, India | |||
| BDR Pharmaceuticals International Private Limitedthis company | ₹1,080.06 Cr (FY 2025) | ₹233.5 Cr | 21.6% | 2.0% | 1,437 | Mumbai, Maharashtra, India |
To see the full peer comparison of BDR Pharmaceuticals International Private Limited, buy the company report.
Auditor
BDR Pharmaceuticals International Private Limited is audited by Deloitte Haskins & Sells LLP for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Deloitte Haskins & Sells LLP | FY 2025 | 117366W/W-100018 |
Shareholding
The shareholding of BDR Pharmaceuticals International Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of BDR Pharmaceuticals International Private Limited, buy the company report.
Charges & borrowings
Open charges
None
Satisfied charges
₹9 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 15 Mar 2006 | 80015564 | Abn Amro Bank N. V. | ₹9 Cr | Satisfied |
To see the full charge records of BDR Pharmaceuticals International Private Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
BDR Pharmaceuticals International Private Limited has 6 deals on record (3 funding rounds, 3 secondary share transfers), with disclosed funding of ₹750.47 Cr; the latest was in September 2024.
Total deals
6
Funding rounds
3
Secondary share transfers
3
Disclosed funding
₹750.47 Cr
Deals on record (5 of 6)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2024 | Secondary share transfer | Undisclosed | Buyer: Marigold Wealth Trust, Shah Family Private Trust Seller: 4 individuals |
| Mar 2024 | Secondary share transfer | Undisclosed | Buyer: Metropolitan Media Company Limited Seller: Dhrmayug Investments Limited |
| May 2022 | Funding round · Series A | ₹496.99 Cr | Investors: Multiples Private Equity, State Bank Of India, Dhrmayug Investments Limited |
| Apr 2022 | Secondary share transfer | Undisclosed | Seller: 2 individuals |
| Sep 2007 | Funding round | ₹49 Lakh | Investors: 2 individuals |
To see the full deal history of BDR Pharmaceuticals International Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
BDR Pharmaceuticals International Private Limited has 55 court cases on record: 38 filed by BDR Pharmaceuticals International, 17 filed against it. 27 cases are pending and 28 are disposed.
Total cases
55
Filed by the company
38
Filed against the company
17
Pending
27
Disposed
28
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 27 | 4 | 18 |
| High courts | 24 | 12 | 6 |
| Supreme Court | 4 | 1 | 3 |
Cases on record (5 of 55)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai CMM Courts, Maharashtra | Court case (SUMMARY) | Filed by the company against Ruchi Medical Private Limited | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summary Cases) | Filed by the company against Doctorsmed Pharmaceuticals Pvt Ltd | Pending |
| High Court, MAHARASHTRA | Writ petition | Filed against the company by Priyanka Infra Private Limited and Ors | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (SUMMONS CASES SS) | Filed by the company against Priyanka Infra Private Limited and 2 others | Pending |
| High Court of Delhi | Commercial suit | Filed against the company by Sun Pharma Laboratories Limited | Pending |
To see the full case history of BDR Pharmaceuticals International Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
BDR Pharmaceuticals International Private Limited has 16 MSME Form 1 returns on record between 2019 and 2024, listing 667 overdue payments to 32 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 32)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Bee Pharmo Labs Pvt Limited | |||
| Memphis Vision Care Private Limited | |||
| Megastar Products Private Limited | |||
| Vizitech Packaging | |||
| Shreyas Cartons Private Limited |
To see the full MSME payment records of BDR Pharmaceuticals International Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
BDR Pharmaceuticals International has 6 subsidiary companies and 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
6
Subsidiary companies
1
Associated companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Cibeles Pharmaceuticals Private Limited | U24100MH2019PTC379982 | |
| BDR Life Science Private Limited | U24230GJ1993PTC020258 | |
| Virdev Intermediates Private Limited | U24230GJ1994PTC021189 | |
| Magnum Chemi-Gran Private Limited | U24230TG2005PTC046533 | |
| Nutrigene Biosciences Private Limited | U24290TG2020PTC145055 | |
| Spinos Life Science & Research Private Limited | U85200TZ2016PTC027449 |
To see the full group structure of BDR Pharmaceuticals International Private Limited, buy the company report.
Employees & EPFO
BDR Pharmaceuticals International Private Limited has a workforce of 1,437 employees on its EPFO records as of Dec 30, 2025, across 1 active EPFO establishment.
Employee count
1,437
Active EPFO establishments
1
Employee growth
19.45%
GST
BDR Pharmaceuticals International has 15 GST registrations: 11 active and 4 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
15
Active
11
Cancelled / inactive
4
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCB9286B1ZO | Maharashtra | Active | 01 Jul 2017 |
| 27AABCB9286B2ZN | Maharashtra | Active | 05 Feb 2025 |
| 02AABCB9286B1Z0 | Himachal Pradesh | Active | 01 Jul 2017 |
| 05AABCB9286B1ZU | Uttarakhand | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of BDR Pharmaceuticals International Private Limited, buy the company report.
Recent activity
BDR Pharmaceuticals International Private Limited has 12 board changes on record since 2008: 6 appointments and 6 cessations. The latest: Dharmesh Mahendra Shah was appointed as Director on 13 May 2022.
AGM
Bdr Pharmaceuticals International Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Bdr Pharmaceuticals International Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Appointed
Dharmesh Mahendra Shah was appointed as Director.
Ceased
Dheer Dharmesh Shah ceased to be Director.
Appointed
Manish Gaur was appointed as Nominee Director.
Ceased
Jayesh Shantilal Trivedi ceased to be Additional Director.
Appointed
Jayesh Shantilal Trivedi was appointed as Director.
Ceased
Vijay Chhabildas Shah ceased to be Director.
Ceased
Dharmesh Mahendra Shah ceased to be Director.
Charges
A charge registered on 15 Mar 2006 via Charge ID 80015564 with Abn Amro Bank N. V. was fully satisfied on 22 Jan 2019.
Appointed
Aravind Manappa Badiger was appointed as Director.
Appointed
Raheel Dharmesh Shah was appointed as Director.
6 earlier events are in the company report.
News
Frequently asked questions
BDR Pharmaceuticals International is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 September 2002 (24+ years old) and is registered under CIN U24230MH2002PTC137329.
BDR Pharmaceuticals International has 6 current directors:
- Aravind Manappa Badiger - Director
- Jayesh Shantilal Trivedi - Director
- Tejash Vijay Shah - Director
- Dharmesh Mahendra Shah - Director
- Manish Gaur - Nominee Director
- Raheel Dharmesh Shah - Director
The latest financial statements of BDR Pharmaceuticals International on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of BDR Pharmaceuticals International is 27AABCB9286B1ZO, registered in Maharashtra. The company has 15 GST registrations in all, of which 11 are active and 4 are cancelled or inactive. Other active GSTINs include 27AABCB9286B2ZN (Maharashtra), 02AABCB9286B1Z0 (Himachal Pradesh), 05AABCB9286B1ZU (Uttarakhand).
The CIN (Corporate Identification Number) of BDR Pharmaceuticals International is U24230MH2002PTC137329. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
BDR Pharmaceuticals International has 55 court cases on record: 38 filed by the company and 17 filed against it. 27 are pending. Most are in the district courts.
BDR Pharmaceuticals International was incorporated on 24 September 2002, making it 24+ years old. It is registered with the Registrar of Companies, Mumbai.
BDR Pharmaceuticals International has 6 deals on record (3 funding rounds, 3 secondary share transfers), with disclosed funding of ₹750.47 Cr; the latest was in September 2024.
The peers of BDR Pharmaceuticals International by revenue are Cipla Health Limited, Neon Laboratories Limited, Corona Remedies Limited, Hetero Healthcare Limited, Vasudha Pharma Chem Limited and 5 more, all in the Pharma industry (API Manufacturers, Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Dharmesh Mahendra Shah was appointed as Director on 13 May 2022. Dheer Dharmesh Shah ceased to be Director on 12 May 2022. Manish Gaur was appointed as Nominee Director on 12 May 2022. BDR Pharmaceuticals International has 12 board changes on record in total.
BDR Pharmaceuticals International has 16 MSME Form 1 returns on record between 2019 and 2024, listing 667 overdue payments to 32 micro and small suppliers. The latest return was filed on 30 Apr 2024.
BDR Pharmaceuticals International can be reached through the website bdrpharma.com. Its registered office is in Mumbai, Maharashtra, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages